Enhancer of Zeste Homolog 2 Protein

"Enhancer of Zeste Homolog 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation at the PROMOTER REGIONS of the circadian genes and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS.

Descriptor ID	D000071221
MeSH Number(s)	D05.500.781.750.250 D08.811.913.555.500.800.400.500.500 D12.776.660.235.600.200.250 D12.776.664.235.800.200.250 D12.776.930.780.890.200.250
Concept/Terms	Enhancer of Zeste Homolog 2 Protein Enhancer of Zeste Homolog 2 Protein Lysine N-Methyltransferase-6 Lysine N Methyltransferase 6 Histone-Lysine N-Methyltransferase EZH2 EZH2, Histone-Lysine N-Methyltransferase Histone Lysine N Methyltransferase EZH2 Enhancer of Zeste Homolog 2

Below are MeSH descriptors whose meaning is more general than "Enhancer of Zeste Homolog 2 Protein".

Chemicals and Drugs [D]
Macromolecular Substances [D05]
Multiprotein Complexes [D05.500]
Polycomb-Group Proteins [D05.500.781]
Polycomb Repressive Complex 2 [D05.500.781.750]
Enhancer of Zeste Homolog 2 Protein [D05.500.781.750.250]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
One-Carbon Group Transferases [D08.811.913.555]
Methyltransferases [D08.811.913.555.500]
Protein Methyltransferases [D08.811.913.555.500.800]
Histone-Lysine N-Methyltransferase [D08.811.913.555.500.800.400]
Polycomb Repressive Complex 2 [D08.811.913.555.500.800.400.500]
Enhancer of Zeste Homolog 2 Protein [D08.811.913.555.500.800.400.500.500]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Nuclear Proteins [D12.776.660]
Chromosomal Proteins, Non-Histone [D12.776.660.235]
Polycomb-Group Proteins [D12.776.660.235.600]
Polycomb Repressive Complex 2 [D12.776.660.235.600.200]
Enhancer of Zeste Homolog 2 Protein [D12.776.660.235.600.200.250]
Nucleoproteins [D12.776.664]
Chromosomal Proteins, Non-Histone [D12.776.664.235]
Polycomb-Group Proteins [D12.776.664.235.800]
Polycomb Repressive Complex 2 [D12.776.664.235.800.200]
Enhancer of Zeste Homolog 2 Protein [D12.776.664.235.800.200.250]
Transcription Factors [D12.776.930]
Repressor Proteins [D12.776.930.780]
Polycomb-Group Proteins [D12.776.930.780.890]
Polycomb Repressive Complex 2 [D12.776.930.780.890.200]
Enhancer of Zeste Homolog 2 Protein [D12.776.930.780.890.200.250]

Below are MeSH descriptors whose meaning is related to "Enhancer of Zeste Homolog 2 Protein".

Below are MeSH descriptors whose meaning is more specific than "Enhancer of Zeste Homolog 2 Protein".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Enhancer of Zeste Homolog 2 Protein" by people in this website by year, and whether "Enhancer of Zeste Homolog 2 Protein" was a major or minor topic of these publications.

Bar chart showing 26 publications over 15 distinct years, with a maximum of 4 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2004	0	1	1
2006	0	1	1
2007	0	2	2
2010	0	1	1
2011	0	3	3
2012	0	1	1
2013	0	2	2
2016	1	0	1
2017	2	0	2
2018	2	2	4
2019	0	2	2
2020	2	1	3
2022	1	0	1
2024	0	1	1

Below are the most recent publications written about "Enhancer of Zeste Homolog 2 Protein" by people in Profiles.

Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol. 2024 12; 25(12):1589-1601.

View in: PubMed
Puzyrenko A, Kumar SN, Pantazis CG, Iczkowski KA. Inverse co-expression of EZH2 and acetylated H3K27 in prostatic tissue. Ann Diagn Pathol. 2022 Aug; 59:151956.

View in: PubMed
Cheng Y, Liao S, Xu G, Hu J, Guo D, Du F, Contreras A, Cai KQ, Peri S, Wang Y, Corney DC, Noronha AM, Chau LQ, Zhou G, Wiest DL, Bellacosa A, Wechsler-Reya RJ, Zhao Y, Yang ZJ. NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma. Cell Rep. 2020 06 23; 31(12):107782.

View in: PubMed
Wasson CW, Abignano G, Hermes H, Malaab M, Ross RL, Jimenez SA, Chang HY, Feghali-Bostwick CA, Del Galdo F. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann Rheum Dis. 2020 04; 79(4):507-517.

View in: PubMed
Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, Borowsky ME, Kossenkov AV, Liu Q, Zhang R. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell. 2020 02 10; 37(2):157-167.e6.

View in: PubMed
Johnson WT, Mishra A. The EZ-riding NK/T-cell lymphoma. Blood. 2019 12 05; 134(23):1999-2000.

View in: PubMed
Lu C, Sidoli S, Kulej K, Ross K, Wu CH, Garcia BA. Coordination between TGF-? cellular signaling and epigenetic regulation during epithelial to mesenchymal transition. Epigenetics Chromatin. 2019 02 08; 12(1):11.

View in: PubMed
Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun. 2018 10 08; 9(1):4116.

View in: PubMed
Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129.

View in: PubMed
Roman J, Mutsaers SE. Epigenetic Control of CXCL10: Regulating the Counterregulator in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2018 04; 58(4):419-420.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement